In an effort to develop novel radiopharmaceuticals and address unmet needs in oncology, Radiopharm Theranostics Ltd (ASX:RAD) has inked a multi-year strategic research partnership with GenesisCare, a leading global provider of integrated cancer care and theranostic research.
Through the partnership, the companies will conduct Phase 1 clinical trials in Australia to study the safety and tolerability of novel radiopharmaceuticals.
GenesisCare’s Contract Research Organisation (CRO) and Imaging Research Organisation (IRO) have been engaged to implement three Phase 1 clinical trials in Australia involving Radiopharm’s platform of radiopharmaceutical nanobodies.
New oncological frontier
“Radiopharmaceuticals are quickly becoming a highly promising therapeutic frontier in oncology, offering new hope to patients who may have exhausted all other treatment options,” Radiopharm Theranostics CEO and managing director Riccardo Canevari said.
“We are delighted to be extending and strengthening our partnership with GenesisCare, a world leader in cancer care, to advance the future of radiopharmaceuticals and improve access to innovative therapies for patients all over the world.”
The three Phase 1 clinical trials to be conducted by GenesisCare for Radiopharm under the research partnership are:
- Phase 1 trial involving Radiopharm’s proprietary nanobody from its Nano-mAbs platform which targets the PDL1 expression in non-small cell lung cancer
- Phase 1 trial involving Radiopharm’s PTPu targeting peptide in Brain Tumors
- Phase 1 trial involving Radiopharm’s PSA targeting antibody which targets free human prostate kallikrein (PSA) in prostate cancer cells.
Read: Radiopharm Theranostics welcomes additional data from Phase 2a brain metastases trial
“We are delighted to be partnering with Radiopharm on its exciting pipeline of research in Australia,” GenesisCare chief scientific officer, research and insights Dr Danielle Meyrick, PhD said.
“This R&D collaboration brings together two Australian-founded healthcare companies who share an interest in investigating and developing new therapies in Australia.”
Radiopharmaceuticals are designed to deliver small doses of radiation to specifically targeted cells for either therapeutic or diagnostic purposes, referred to as theranostics when used in concert.
RAD has a pipeline of six distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer, in pre-clinical and clinical stages of development from some of the world’s leading universities and institutes.